Does low-dose aspirin (81 mg daily) reduce the risk of gastric cancer and prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Low-Dose Aspirin and Protection Against Gastric and Prostate Cancer

While low-dose aspirin (81 mg daily) shows promising evidence for reducing gastric cancer risk, particularly with long-term use (≥3-5 years), the evidence for prostate cancer protection is conflicting and does not support a recommendation for aspirin use specifically for prostate cancer prevention.

Gastric Cancer: Evidence Supports Protective Effect

The evidence for gastric cancer prevention is compelling and consistent across multiple high-quality studies:

Magnitude of Risk Reduction

  • Low-dose aspirin reduces gastric cancer risk by approximately 40-54% 1
  • A 2020 UK population-based study demonstrated an adjusted odds ratio of 0.46 (95% CI: 0.38-0.57), representing a 54% risk reduction 1
  • A 2025 meta-analysis confirmed this dose-response relationship with an overall relative risk of 0.73 (95% CI: 0.57-0.94) for highest versus lowest aspirin doses 2

Duration Matters Significantly

The protective effect requires sustained use:

  • Significant risk reduction appears after 3+ years of continuous use 3
  • A Korean nationwide cohort study showed adjusted hazard ratio of 0.40 (95% CI: 0.16-0.98) for users taking aspirin >3 years 3
  • Each additional year of aspirin use conferred incremental benefit (aHR 0.85 per year; 95% CI: 0.73-0.99) 3

Dose Considerations

  • The protective effect is evident even at 75 mg/day, the lowest therapeutic dose 1
  • Effects remain consistent across lag-time analyses, supporting a true biological effect rather than detection bias 1

Prostate Cancer: Evidence is Conflicting and Inconclusive

The prostate cancer data presents a more complex and contradictory picture:

Mixed Findings

  • One 2016 Italian retrospective cohort showed potential benefit (HR = 0.64; 95% CI: 0.48-0.86), with stronger effects for ≥5 years use (HR = 0.43; 95% CI: 0.21-0.91) 4
  • However, a 2020 Danish study found no overall protective effect and concerning signals: reduced risk for nonaggressive disease (HR 0.79) but increased risk for aggressive prostate cancer (HR 1.27; 95% CI: 1.00-1.61) with high-dose aspirin use 5
  • A 2023 Spanish study suggested modest protection (aHR: 0.6; 95% CI: 0.5-0.7) 6

Critical Concern

The potential for increased aggressive prostate cancer risk with aspirin use is particularly troubling 5, as aggressive disease drives prostate cancer mortality. This differential effect by disease aggressiveness makes any blanket recommendation problematic.

Current Guideline Position

The USPSTF and expert consensus do not currently endorse aspirin use solely for cancer prevention 7. The 2016 guidelines explicitly state that "additional studies are needed to examine the potential that aspirin may be effective in decreasing the risk of cancers other than CRC" and specifically mention that findings for prostate cancer (along with esophageal, breast, and lung) require "validating these findings and estimating their relative and absolute impacts" before population-based guidelines can be advanced 7.

Practical Clinical Approach

For Gastric Cancer Prevention:

  • Consider low-dose aspirin (81 mg daily) in patients with elevated gastric cancer risk (family history, H. pylori infection history, intestinal metaplasia) who also have cardiovascular indications
  • Emphasize that benefit requires ≥3-5 years of continuous use 3
  • The effect appears stronger in Asian populations 2
  • Balance against bleeding risks, particularly in patients >60 years, those with prior ulcer history, or concurrent anticoagulant use 8

For Prostate Cancer Prevention:

  • Do not recommend aspirin specifically for prostate cancer prevention given conflicting evidence and concerning signals for increased aggressive disease 5
  • If patients are already taking aspirin for cardiovascular indications, counsel them that prostate cancer protection is uncertain and may vary by disease aggressiveness

Common Pitfalls to Avoid:

  • Don't expect short-term cancer prevention benefits – gastric cancer protection requires years of continuous use
  • Don't ignore bleeding risk assessment – major gastrointestinal bleeding risk increases with age, particularly >60 years 8
  • Don't recommend aspirin for cancer prevention alone – current guidelines only support aspirin when cardiovascular benefits are also present 7

References

Related Questions

Does low-dose aspirin (75–100 mg daily) prevent gastric cancer?
Is there evidence that low-dose aspirin (81 mg daily) can reduce the incidence of skin cancer?
Does taking low-dose aspirin reduce the formation of colon polyps?
Does aspirin cause alopecia in women?
Should I continue low‑dose aspirin (81 mg daily) after 15 years of use for colorectal cancer prevention?
Does daily low‑dose aspirin (81 mg) reduce cancer risk, particularly colorectal cancer, and what are the associated benefits and risks?
A patient who received an intra‑articular knee corticosteroid injection 6 weeks ago, can they receive another steroid injection today for overall inflammation?
What are the differential diagnoses for a persistent rash with papular lesions located in the intermammary area, nape of the neck near the hairline, and lower back, and what medications would you recommend?
What is the appropriate valacyclovir dosing and safety considerations for a 16-year-old male with normal renal function for treatment of herpes simplex virus or varicella‑zoster virus infections?
In an 87-year-old man taking spironolactone, betahistine (Betaserc), and apixaban, what is the differential diagnosis and recommended work‑up for sudden dizziness, eructation, flatulence, and epigastric irritation?
For a patient with a solitary kidney and no renal impairment, what is the best analgesic for back, shoulder, or muscle pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.